CN Patent
CN107810006B — 用于治疗失眠的组合物
Assigned to Sanitary Material R&d Management Co ltd · Expires 2021-03-30 · 5y expired
What this patent protects
在本发明中,化合物例如(1R,2S)‑2‑(((2,4‑二甲基嘧啶‑5‑基)氧基)甲基)‑2‑(3‑氟苯基)‑N‑(5‑氟吡啶‑2‑基)环丙烷甲酰胺已被发现是有效的食欲素受体拮抗剂,并且可用于治疗睡眠障碍例如失眠,以及用于其他治疗用途。
USPTO Abstract
在本发明中,化合物例如(1R,2S)‑2‑(((2,4‑二甲基嘧啶‑5‑基)氧基)甲基)‑2‑(3‑氟苯基)‑N‑(5‑氟吡啶‑2‑基)环丙烷甲酰胺已被发现是有效的食欲素受体拮抗剂,并且可用于治疗睡眠障碍例如失眠,以及用于其他治疗用途。
Drugs covered by this patent
- Dayvigo (LEMBOREXANT) · Eisai
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.